134
R. Gitto et al. / Il Farmaco 57 (2002) 129–134
[20] D. Bleakman, B.A. Ballyk, D.D. Schoepp, A.J. Palmer, C.P.
[3] W.C. McEntee, T.H. Crook, Glutamate, its role in learning,
Bath, E.F. Sharpe, M.L. Wooley, H.R. Bufton, R.K. Kamboj, I.
Tarnawa, D. Lodge, Activity of 2,3-benzodiazepines at native rat
and recombinant human glutamate receptors in vitro: stereospe-
cificity and selectivity profiles, Neuropharmacology 35 (1996)
1689–1702.
memory, and the aging brain, Psychopharmacology 111 (1993)
391–401.
[4] R. Dingledine, K. Borges, D. Bowie, S.R. Traynelis, The gluta-
mate receptor ion channels, Pharmacol. Rev. 51 (1999) 7–61.
[5] D.T. Monaghan, R.J. Wenthold (Eds.), The Ionotropic Gluta-
mate Receptors, Humana Press, New Jersey, 1997.
[6] C. Rosenmund, Y. Stern-Bach, C.F. Stevens, The tetrameric
structure of a glutamate receptor channel, Science 280 (1998)
1596–1599.
[7] M.J. Sutcliffe, Z.G. Wo, R.E. Oswald, Three dimensional mod-
els of non-NMDA glutamate receptors, Biophys. J. 70 (1996)
1575–1589.
[8] G.J. Lees, Therapeutic potential of AMPA receptor ligands in
neurological disorders, CNS Drugs 5 (1996) 51–74.
[9] R. Gill, D. Lodge, Pharmacology of AMPA antagonists and
their role in neuroprotection, in: Neuroprotective Agents and
Cerebral Ischaemia, Academic Press, San Diego, 1997, pp. 197–
232.
[10] G.J. Lees, Pharmacology of AMPA/kainate receptor ligands and
their therapeutic potential in neurological and psychiatric disor-
ders, Drugs 59 (2000) 33–78.
[11] Z. Lin, P.K. Kadaba, Molecular targets for the rational design
of antiepileptic drugs and related neuroprotective agents, Med.
Res. Rev. 17 (1997) 537–572.
[12] M.A. Rogawski, S.D. Donevan, AMPA receptors in epilepsy
and as targets for antiepileptic drugs, Adv. Neurol. 79 (1999)
947–963.
[13] A. Chimirri, R. Gitto, M. Zappala`, AMPA receptor antagonists,
Exp. Opin. Ther. Patents 9 (1999) 557–570.
[14] A.G. Chapman, Z. Al-Zubaidy, B.S. Meldrum, Aniracetam re-
verses the anticonvulsant action of NBQX and GYKI 52466 in
DBA/2 mice, Eur. J. Pharmacol. 231 (1993) 301–303.
[15] S.D. Donevan, M.A. Rogawski, GYKI 52466, a 2,3-benzodi-
[21] G. De Sarro, A. Chimirri, A. De Sarro, R. Gitto, S. Grasso, P.
Giusti, A.G. Chapman, GYKI 52466 and related 2,3-benzodi-
azepines as anticonvulsant agents in DBA/2 mice, Eur. J. Phar-
macol. 294 (1995) 411–422.
[22] A. Chimirri, G. De Sarro, A. De Sarro, R. Gitto, S. Grasso, S.
Quartarone, M. Zappala`, P. Giusti, V. Libri, A. Constanti, A.G.
Chapman,
1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones:
novel AMPA receptor antagonists, J. Med. Chem. 40 (1997)
[23] M. Rizzo, V.A. Sinopoli, R. Gitto, M. Zappala`, G. De Sarro, A.
Chimirri, High-performance liquid chromatography determina-
tion of new 2,3-benzodiazepines, J. Chromat. B 705 (1998)
149–153.
[24] G. De Sarro, M. Rizzo, V.A. Sinopoli, R. Gitto, A. De Sarro,
M. Zappala`, A. Chimirri, Relationship between anticonvulsant
activity and plasma level of some 2,3-benzodiazepines in geneti-
cally epilepsy prone rats, Pharmacol. Biochem. Behav. 61 (1998)
215–220.
[25] M. Rizzo, G. De Sarro, M. Zappala`, A. Chimirri, Determination
of new 2,3-benzodiazepines in rat plasma using high-perfor-
mance liquid chromatography with ultraviolet detection, J.
Chromat. B 731 (1999) 207–215.
[26] G. De Sarro, M. Rizzo, C. Spagnolo, R. Gitto, A. De Sarro, G.
Scotto, M. Zappala`, A. Chimirri, Anticonvulsant activity and
plasma level of some 2,3-benzodiazepin-4-ones (CFMs) in genet-
ically epilepsy prone rats, Pharmacol. Biochem. Behav. 63 (1999)
621–627.
[27] A. Chimirri, G. De Sarro, A. De Sarro, R. Gitto, S. Quartarone,
M. Zappala`, A. Constanti, V. Libri, 3,5-Dihydro-4H-2,3-benzo-
diazepine-4-thiones: a new class of AMPA receptor antagonists,
J. Med. Chem. 41 (1998) 3409–3416.
[28] A. Chimirri, M. Zappala`, R. Gitto, S. Quartarone, F. Bevacqua,
Synthesis and structural features of 11H-tetrazolo[1,5-c][2,3]-
benzodiazepines, Heterocycles 51 (1999) 1303–1309.
[29] A. Chimirri, F. Bevacqua, R. Gitto, S. Quartarone, M. Zappala`,
A. De Sarro, L. Maciocco, G. Biggio, G. De Sarro, Synthesis
and anticonvulsant activity of new 11H-triazolo[4,5-
c][2,3]benzodiazepines, Med. Chem. Res. 9 (1999) 203–212.
[30] M. Zappala`, R. Gitto, F. Bevacqua, S. Quartarone, A. Chimirri,
M. Rizzo, G. De Sarro, A. De Sarro, Synthesis and evaluation
of pharmacological and pharmacokinetic properties of 11H-
azepine, is
a highly selective, noncompetitive antagonist of
AMPA/Kainate receptor responses, Neuron 10 (1993) 51–59.
[16] M.A. Rogawski, Therapeutic potential of excitatory amino acid
antagonists: channel blockers and 2,3-benzodiazepines, Trends
Pharmacol. Sci. 14 (1993) 325–331.
[17] S.D. Donevan, S.I. Yamaguchi, M.A. Rogawski, Non-N-methyl-
D
-aspartate receptor antagonism by 3-N-substituted 2,3-benzodi-
azepines: relationship to anticonvulsant activity, J. Pharmacol.
Exp. Ther. 271 (1994) 25–29.
[18] I. Tarnawa, P. Berzsenyi, F. Andrasi, P. Botka, T. Hamori, I.
Ling, J. Ko¨ro¨si, Structure–activity relationships of 2,3-benzodi-
azepine compounds with glutamate antagonistic action, Bioorg.
Med. Chem. Lett. 3 (1993) 99–104.
[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones,
Chem. 43 (2000) 4834–4839.
J.
Med.
[19] D. Lodge, A. Bond, M. O’Neill, C.A. Hicks, M.G. Jones,
Stereoselective effects of 2,3-benzodiazepines in vivo: Electro-
physiology and neuroprotection studies, Neuropharmacology 35
(1996) 1681–1688.
[31] A. Chimirri, R. Gitto, M. Zappala`, A. De Sarro, G. De Sarro,
Synthesis and pharmacological evaluation of 4-aryl-6,7-
dimethoxyphthalazines as anticonvulsant agents, Med. Chem.
Res. 10 (2000) 1–10.